FEP promotes generic Rxs; no co-pay for first four mail orders

5 October 2008

The USA's Blue Cross and Blue Shield government-wide Service Benefit Plan (Federal Employee Program) will waive Standard Option members' first four mail order generic drug co-pays as part of their 2009 benefits package, says the Blue Cross and Blue Shield Association (BCBSA).

To further encourage federal employees to use generic medicines, all 2009 Standard Option member mail order generic co-pays, after the first four prescriptions, are unchanged from 2008. Additionally, members will save 5% on co-insurance costs for generic drugs purchased from retail outlets as compared to last year.

According to Jena Estes, vice president of FEP, BCBSA, "these benefits will help FEP Standard Option members reap the cost-saving benefits of generic prescriptions. Generic medications offer the equivalent effectiveness as brand-name prescriptions, but at a much lower cost."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight